Form 4: Zimmer Biomet Executive Earns 4,692 Performance RSUs

Chad F. Phipps, Sr. VP/Chief Legal Corporate Affairs & Secretary at Zimmer Biomet Holdings, Inc., earned 4,692 performance-based Restricted Stock Units.

Summary

• Chad F. Phipps, a Senior Vice President and Chief Legal Corporate Affairs & Secretary at Zimmer Biomet Holdings, Inc. (ZBH), earned 4,692 performance-based Restricted Stock Units (RSUs).
• These RSUs were granted on March 6, 2023, with the number earned contingent on performance conditions met during the 2023-2025 period.
• The performance determination was made on February 19, 2026, resulting in the earning of 4,692 RSUs.
• The earned RSUs are scheduled to vest on March 6, 2026, converting into shares of company common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating that the company's performance targets for the 2023-2025 period were met, leading to the vesting of executive performance-based compensation.

Positives

• An executive earned a significant number of performance-based Restricted Stock Units (4,692), indicating successful achievement of performance conditions over the 2023-2025 period.
• The vesting of these RSUs on March 6, 2026, aligns executive compensation with long-term company performance and shareholder interests.

Future Outlook

The vesting of 4,692 performance-based Restricted Stock Units on March 6, 2026, represents a future conversion of these contingent rights into common stock, aligning executive incentives with future company performance.

Industry Context

StockSavvy.ai notes that performance-based Restricted Stock Units are a common executive compensation tool in the medical device industry, including companies like Stryker and Medtronic, designed to align executive incentives with long-term shareholder value creation and operational performance. The successful earning of these units suggests the company met its internal performance targets for the specified period.

Comparison to Industry Standards

• Performance-based RSU grants are a standard practice in the medical technology sector, similar to compensation structures at peers like Stryker Corporation and Medtronic plc, which also utilize long-term incentive plans tied to financial and operational metrics.
• The specific number of RSUs earned (4,692) is relative to the executive's role and the company's compensation philosophy, and without specific performance targets, a direct quantitative comparison to individual grants at other companies is not feasible. However, the mechanism itself is consistent with industry best practices for executive retention and motivation.

Stakeholder Impact

• Shareholders: The vesting of performance-based RSUs aligns executive incentives with shareholder interests, as the units were earned based on company performance.
• Employees: This transaction reflects the company's executive compensation structure, which may influence broader employee incentive programs.

Next Steps

• The 4,692 earned Restricted Stock Units are scheduled to vest on March 6, 2026, at which point they will convert into shares of Zimmer Biomet Holdings, Inc. common stock.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event where performance-based Restricted Stock Units were earned. It reflects the achievement of internal performance targets but does not provide new material information about the company's financial health or strategic direction that would warrant a change in investment recommendation. It's a neutral event for current investors, reinforcing a 'hold' stance.

Keywords

Zimmer Biomet, ZBH, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Performance-based, Chad F. Phipps, SEC Form 4